Excitotoxicity in Neurological Diseases: New Therapeutic Challenge
It can be reasonably anticipated that, over the next generations, the proportion of elderly people will remarkably increase and, with this, the number ofpersons suffering from acute (e.g. cerebral ischemia) or chronic neurodegenerative disorders. To date, approved drugs only alleviate the symptoms o...
Gespeichert in:
Weitere Verfasser: | , |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Boston, MA
Springer US
2004
|
Schlagworte: | |
Online-Zugang: | DE-355 Volltext |
Zusammenfassung: | It can be reasonably anticipated that, over the next generations, the proportion of elderly people will remarkably increase and, with this, the number ofpersons suffering from acute (e.g. cerebral ischemia) or chronic neurodegenerative disorders. To date, approved drugs only alleviate the symptoms ofthese diseases (for instance, acetylcholinesterase inhibitors in Alzheimer disease and L-dopa and dopamine-agonists in Parkinson disease), while none seems to stop the progression of the degenerative processes underlying them. The development of effective preventive or protective therapies has been impeded by the limitations of our knowledge of the causes and the mechanisms by which neurons die in neurodegenerative disorders. Evidence accumulated in the past 20 years indicated that the major excitatory neurotransmitter glutamate may play a role as neurotoxin in several conditions. In particular, the glutamatergic system dysfunction seems to be an early event working as a common pathway in the pathogenesis ofa large number ofacute and chronic neurological disorders, in strict conjunction with other important mechanisms, such as oxidative stress and energetic failure, and probably triggered by different mechanisms in various diseases. In consideration of that, drug discovery efforts over the last decade have been focused on the search for drugs that either reduce glutamate synaptic levels or block its postsynaptic effects. Despite numerous reviews on basic mechanisms and clinical aspects ofthe excitotoxic phenomenon, so far no comprehensive book has covered the topic in all its complexity, starting from basic pharmacological mechanisms, to .animal models of diseases and finally to clinical pathogenic and therapeutic implications |
Beschreibung: | 1 Online-Ressource (XI, 362 p) |
ISBN: | 9781441989598 |
DOI: | 10.1007/978-1-4419-8959-8 |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV046148860 | ||
003 | DE-604 | ||
007 | cr|uuu---uuuuu | ||
008 | 190906s2004 |||| o||u| ||||||eng d | ||
020 | |a 9781441989598 |9 978-1-4419-8959-8 | ||
024 | 7 | |a 10.1007/978-1-4419-8959-8 |2 doi | |
035 | |a (ZDB-2-SBL)978-1-4419-8959-8 | ||
035 | |a (OCoLC)1119016478 | ||
035 | |a (DE-599)BVBBV046148860 | ||
040 | |a DE-604 |b ger |e aacr | ||
041 | 0 | |a eng | |
049 | |a DE-355 | ||
082 | 0 | |a 612.8 |2 23 | |
084 | |a YG 5000 |0 (DE-625)153502:12905 |2 rvk | ||
245 | 1 | 0 | |a Excitotoxicity in Neurological Diseases |b New Therapeutic Challenge |c edited by Carlo Ferrarese, M. Flint Beal |
264 | 1 | |a Boston, MA |b Springer US |c 2004 | |
300 | |a 1 Online-Ressource (XI, 362 p) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
520 | |a It can be reasonably anticipated that, over the next generations, the proportion of elderly people will remarkably increase and, with this, the number ofpersons suffering from acute (e.g. cerebral ischemia) or chronic neurodegenerative disorders. To date, approved drugs only alleviate the symptoms ofthese diseases (for instance, acetylcholinesterase inhibitors in Alzheimer disease and L-dopa and dopamine-agonists in Parkinson disease), while none seems to stop the progression of the degenerative processes underlying them. The development of effective preventive or protective therapies has been impeded by the limitations of our knowledge of the causes and the mechanisms by which neurons die in neurodegenerative disorders. Evidence accumulated in the past 20 years indicated that the major excitatory neurotransmitter glutamate may play a role as neurotoxin in several conditions. In particular, the glutamatergic system dysfunction seems to be an early event working as a common pathway in the pathogenesis ofa large number ofacute and chronic neurological disorders, in strict conjunction with other important mechanisms, such as oxidative stress and energetic failure, and probably triggered by different mechanisms in various diseases. In consideration of that, drug discovery efforts over the last decade have been focused on the search for drugs that either reduce glutamate synaptic levels or block its postsynaptic effects. Despite numerous reviews on basic mechanisms and clinical aspects ofthe excitotoxic phenomenon, so far no comprehensive book has covered the topic in all its complexity, starting from basic pharmacological mechanisms, to .animal models of diseases and finally to clinical pathogenic and therapeutic implications | ||
650 | 4 | |a Neurosciences | |
650 | 4 | |a Neurology | |
650 | 4 | |a Neurosciences | |
650 | 4 | |a Neurology | |
650 | 0 | 7 | |a Excitotoxin |0 (DE-588)4727756-7 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Nervensystem |0 (DE-588)4041643-4 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Krankheit |0 (DE-588)4032844-2 |2 gnd |9 rswk-swf |
689 | 0 | 0 | |a Nervensystem |0 (DE-588)4041643-4 |D s |
689 | 0 | 1 | |a Krankheit |0 (DE-588)4032844-2 |D s |
689 | 0 | 2 | |a Excitotoxin |0 (DE-588)4727756-7 |D s |
689 | 0 | |8 1\p |5 DE-604 | |
700 | 1 | |a Ferrarese, Carlo |4 edt | |
700 | 1 | |a Beal, M. Flint |4 edt | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781402076800 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461347361 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781441989604 |
856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4419-8959-8 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
912 | |a ZDB-2-SBL | ||
940 | 1 | |q ZDB-2-SBL_2000/2004 | |
943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031529037 | |
966 | e | |u https://doi.org/10.1007/978-1-4419-8959-8 |l DE-355 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext |
Datensatz im Suchindex
_version_ | 1807322312170536960 |
---|---|
adam_text | |
any_adam_object | |
author2 | Ferrarese, Carlo Beal, M. Flint |
author2_role | edt edt |
author2_variant | c f cf m f b mf mfb |
author_facet | Ferrarese, Carlo Beal, M. Flint |
building | Verbundindex |
bvnumber | BV046148860 |
classification_rvk | YG 5000 |
collection | ZDB-2-SBL |
ctrlnum | (ZDB-2-SBL)978-1-4419-8959-8 (OCoLC)1119016478 (DE-599)BVBBV046148860 |
dewey-full | 612.8 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 612 - Human physiology |
dewey-raw | 612.8 |
dewey-search | 612.8 |
dewey-sort | 3612.8 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
doi_str_mv | 10.1007/978-1-4419-8959-8 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nmm a2200000zc 4500</leader><controlfield tag="001">BV046148860</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781441989598</subfield><subfield code="9">978-1-4419-8959-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4419-8959-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-1-4419-8959-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119016478</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046148860</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">612.8</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 5000</subfield><subfield code="0">(DE-625)153502:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Excitotoxicity in Neurological Diseases</subfield><subfield code="b">New Therapeutic Challenge</subfield><subfield code="c">edited by Carlo Ferrarese, M. Flint Beal</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XI, 362 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">It can be reasonably anticipated that, over the next generations, the proportion of elderly people will remarkably increase and, with this, the number ofpersons suffering from acute (e.g. cerebral ischemia) or chronic neurodegenerative disorders. To date, approved drugs only alleviate the symptoms ofthese diseases (for instance, acetylcholinesterase inhibitors in Alzheimer disease and L-dopa and dopamine-agonists in Parkinson disease), while none seems to stop the progression of the degenerative processes underlying them. The development of effective preventive or protective therapies has been impeded by the limitations of our knowledge of the causes and the mechanisms by which neurons die in neurodegenerative disorders. Evidence accumulated in the past 20 years indicated that the major excitatory neurotransmitter glutamate may play a role as neurotoxin in several conditions. In particular, the glutamatergic system dysfunction seems to be an early event working as a common pathway in the pathogenesis ofa large number ofacute and chronic neurological disorders, in strict conjunction with other important mechanisms, such as oxidative stress and energetic failure, and probably triggered by different mechanisms in various diseases. In consideration of that, drug discovery efforts over the last decade have been focused on the search for drugs that either reduce glutamate synaptic levels or block its postsynaptic effects. Despite numerous reviews on basic mechanisms and clinical aspects ofthe excitotoxic phenomenon, so far no comprehensive book has covered the topic in all its complexity, starting from basic pharmacological mechanisms, to .animal models of diseases and finally to clinical pathogenic and therapeutic implications</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurosciences</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurosciences</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Excitotoxin</subfield><subfield code="0">(DE-588)4727756-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nervensystem</subfield><subfield code="0">(DE-588)4041643-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krankheit</subfield><subfield code="0">(DE-588)4032844-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Nervensystem</subfield><subfield code="0">(DE-588)4041643-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Krankheit</subfield><subfield code="0">(DE-588)4032844-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Excitotoxin</subfield><subfield code="0">(DE-588)4727756-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrarese, Carlo</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beal, M. Flint</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781402076800</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461347361</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781441989604</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4419-8959-8</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031529037</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4419-8959-8</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
id | DE-604.BV046148860 |
illustrated | Not Illustrated |
indexdate | 2024-08-14T00:54:30Z |
institution | BVB |
isbn | 9781441989598 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031529037 |
oclc_num | 1119016478 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR |
owner_facet | DE-355 DE-BY-UBR |
physical | 1 Online-Ressource (XI, 362 p) |
psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
publishDate | 2004 |
publishDateSearch | 2004 |
publishDateSort | 2004 |
publisher | Springer US |
record_format | marc |
spelling | Excitotoxicity in Neurological Diseases New Therapeutic Challenge edited by Carlo Ferrarese, M. Flint Beal Boston, MA Springer US 2004 1 Online-Ressource (XI, 362 p) txt rdacontent c rdamedia cr rdacarrier It can be reasonably anticipated that, over the next generations, the proportion of elderly people will remarkably increase and, with this, the number ofpersons suffering from acute (e.g. cerebral ischemia) or chronic neurodegenerative disorders. To date, approved drugs only alleviate the symptoms ofthese diseases (for instance, acetylcholinesterase inhibitors in Alzheimer disease and L-dopa and dopamine-agonists in Parkinson disease), while none seems to stop the progression of the degenerative processes underlying them. The development of effective preventive or protective therapies has been impeded by the limitations of our knowledge of the causes and the mechanisms by which neurons die in neurodegenerative disorders. Evidence accumulated in the past 20 years indicated that the major excitatory neurotransmitter glutamate may play a role as neurotoxin in several conditions. In particular, the glutamatergic system dysfunction seems to be an early event working as a common pathway in the pathogenesis ofa large number ofacute and chronic neurological disorders, in strict conjunction with other important mechanisms, such as oxidative stress and energetic failure, and probably triggered by different mechanisms in various diseases. In consideration of that, drug discovery efforts over the last decade have been focused on the search for drugs that either reduce glutamate synaptic levels or block its postsynaptic effects. Despite numerous reviews on basic mechanisms and clinical aspects ofthe excitotoxic phenomenon, so far no comprehensive book has covered the topic in all its complexity, starting from basic pharmacological mechanisms, to .animal models of diseases and finally to clinical pathogenic and therapeutic implications Neurosciences Neurology Excitotoxin (DE-588)4727756-7 gnd rswk-swf Nervensystem (DE-588)4041643-4 gnd rswk-swf Krankheit (DE-588)4032844-2 gnd rswk-swf Nervensystem (DE-588)4041643-4 s Krankheit (DE-588)4032844-2 s Excitotoxin (DE-588)4727756-7 s 1\p DE-604 Ferrarese, Carlo edt Beal, M. Flint edt Erscheint auch als Druck-Ausgabe 9781402076800 Erscheint auch als Druck-Ausgabe 9781461347361 Erscheint auch als Druck-Ausgabe 9781441989604 https://doi.org/10.1007/978-1-4419-8959-8 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
spellingShingle | Excitotoxicity in Neurological Diseases New Therapeutic Challenge Neurosciences Neurology Excitotoxin (DE-588)4727756-7 gnd Nervensystem (DE-588)4041643-4 gnd Krankheit (DE-588)4032844-2 gnd |
subject_GND | (DE-588)4727756-7 (DE-588)4041643-4 (DE-588)4032844-2 |
title | Excitotoxicity in Neurological Diseases New Therapeutic Challenge |
title_auth | Excitotoxicity in Neurological Diseases New Therapeutic Challenge |
title_exact_search | Excitotoxicity in Neurological Diseases New Therapeutic Challenge |
title_full | Excitotoxicity in Neurological Diseases New Therapeutic Challenge edited by Carlo Ferrarese, M. Flint Beal |
title_fullStr | Excitotoxicity in Neurological Diseases New Therapeutic Challenge edited by Carlo Ferrarese, M. Flint Beal |
title_full_unstemmed | Excitotoxicity in Neurological Diseases New Therapeutic Challenge edited by Carlo Ferrarese, M. Flint Beal |
title_short | Excitotoxicity in Neurological Diseases |
title_sort | excitotoxicity in neurological diseases new therapeutic challenge |
title_sub | New Therapeutic Challenge |
topic | Neurosciences Neurology Excitotoxin (DE-588)4727756-7 gnd Nervensystem (DE-588)4041643-4 gnd Krankheit (DE-588)4032844-2 gnd |
topic_facet | Neurosciences Neurology Excitotoxin Nervensystem Krankheit |
url | https://doi.org/10.1007/978-1-4419-8959-8 |
work_keys_str_mv | AT ferraresecarlo excitotoxicityinneurologicaldiseasesnewtherapeuticchallenge AT bealmflint excitotoxicityinneurologicaldiseasesnewtherapeuticchallenge |